Caramelized.

PD-1 axis inhibition is getting sweeter every day. Camrelizumab is the latest such targeted agent to make it to clinical trials, surviving phase 1 scrutiny among Chinese patients with chemo-refractory metastatic nasopharyngeal cancer. | Fang, Lancet Oncol 2018